Obrion ADC Technologies

Booth No: M305

Characteristic

OBI’s Obrion® ADC technology platform includes three conjugation technologies, GlycOBI®, GlycOBI DUO®, and ThiOBI®, along with a proprietary bifunctional enzyme, EndoSymeOBI®, and a highly stable and hydrophilic linker, HYPrOBI®. OBI’s ADC technology features plug-and-play compatibility with various antibodies, linkers, and payloads, supporting Drug Antibody Ratio (DAR) designs from 2 to 24. Compared to traditional ADC technologies, it overcomes their limitations by enabling more precise payload delivery, and demonstrates superior efficacy and stability in various in vivo studies. Furthermore, the technology has also demonstrated robust GMP manufacturing scalability.